NGM Biopharmaceuticals Third Quarter 2022 Earnings: Beats Expectations

NGM Biopharmaceuticals (NASDAQ:NGM) Third Quarter 2022 Results

Key Financial Results

• Revenue: US$7.91m (down 57% from 3Q 2021).
• Net loss: US$47.3m (loss widened by 64% from 3Q 2021).
• US$0.59 loss per share (further deteriorated from US$0.37 loss in 3Q 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

NGM Biopharmaceuticals Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 3.0%.

Looking ahead, revenue is expected to decline by 2.1% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 4.0%.

Performance of the American Pharmaceuticals industry.

The company's shares are down 4.5% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for NGM Biopharmaceuticals (2 shouldn't be ignored!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.